No profile data available.
Medpace Holdings, Inc. (MEDP) is a healthcare company in the trial phase contract research industry, based in Cincinnati, United States, with about 6,500 full-time employees.
It reported revenue of $2.53 billion for fiscal year 2025, up 19.9% from fiscal year 2024, and net income of $451.12 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $707.33 million, up 17.2% from a year before. United States was its largest region in fiscal year 2025, with 99% of revenue. Its market capitalization was $17.08 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
Medpace reported $2.53 billion in revenue for fiscal year 2025, up 19.9% from $2.11 billion in fiscal year 2024. In Q2 2026 revenue was $707.33 million.
United States: 99% of revenue by region in fiscal year 2025, followed by Foreign (1%).
$17.08 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (trial phase contract research) include Iqvia Holdings Inc. (IQV), Fortrea Holdings Inc. (FTRE), Cannabis Bioscience International Holdings, Inc. (CBIH).